[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Mauritius\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":215},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,76,110,133,163,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100561882","genetic-analysis-of-uncommon-disease-presentations-in-non-us-populations-100561882",false,"NCT06595940","Genetic Analysis of Uncommon Disease Presentations in Non-US Populations","Genomic Sequencing for Evaluation of Uncommon Disease Manifestations Through the Childhood Complex Disease Genomic Section","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Probands aged \\>2 years at enrollment or first-degree relatives of probands (age \\>2 years).\n3. Suspicion of genetic etiology of illness due to strong family history, precocious onset, severity or mildness of phenotype, or all factors being present.\n4. Affected individuals and unaffected family members, determination of clinical criteria for inclusion will be determined by medical record review prior to participation.\n5. Ability of participant and their parent or guardian to understand and have willingness to sign a written informed consent and\u002For assent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Anyone unwilling to provide informed consent (for themselves as adults, on behalf of their children as minors, or on behalf of an adult who is unable to provide consent for themselves) or assent.\n2. Individuals who have undergone diagnostic testing for a genetic condition AND the test results were positive.\n3. Evidence that symptoms are secondary or caused by an undiagnosed condition that is unlikely to have a genetic cause.\n4. In the opinion of the investigator, participant has a condition that would preclude participation in the study by interfering with the participant s ability to engage in the required protocol evaluation and testing.","ALL","2 Years","100 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","Background:\n\nGenetics research over the past 20 years has helped researchers find the causes of many diseases. More powerful tools for genetic testing now exist. Researchers want to use these new tools to learn more about genetic diseases. They want to look for possible genetic causes of unusual diseases. They will focus on people who live outside of the United States and whose access to genetic testing has been limited.\n\nObjective:\n\nTo look for potential genetic sources of diseases among children and their families.\n\nEligibility:\n\nChildren aged 2 to 18 years and their related family members who have or may have a genetic disease. They will reside primarily outside of the US.\n\nDesign:\n\nParticipants will be recruited at sites outside of the US. Participants will be screened. Their existing medical records will be reviewed. They will have a physical exam. They will answer questions about their family history and symptoms. Participants will provide samples for genetic testing. They may have blood drawn. They may spit saliva into a small container. They may have a cotton swab rubbed on the inside of the mouth. The samples will be shipped to the NIH for genetic testing. Participants will be notified if testing reveals a known disease. Participants may be asked to provide new samples to confirm the diagnosis. Local study teams will contact the participants about the results. Participants will also be notified if analysis yields gene variants that may cause disease.",[25,26],"Undiagnosed Diseases","Rare Diseases",[28,29,30,31,32,33],"Genetics","Genomic sequencing","Under-represented populations","Medical genetics","Clinical Phenotype","Uncommon disease","RECRUITING","2026-08-24",{"date":37,"type":38},"2026-08-25","ACTUAL",{"date":40,"type":21},"2026-08-30",{"date":42,"type":21},"2034-08-21",{"name":44,"class":45},"National Human Genome Research Institute (NHGRI)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100565088","phase-2-a-study-to-investigate-efficacy-and-safety-of-sar441566-in-patients-with-crohns-disease-100565088","NCT06637631","A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.","A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease.","SPECIFI-CD","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n1. Male or female participants aged 18 to 75 years at the time of signing the ICF\n2. Confirmed diagnosis of CD for at least 3 months prior to Baseline\n3. Confirmed diagnosis of moderate to severe CD as assessed by:\n\n   * Crohn's Disease Activity Index (CDAI) score and the Simple Endoscopic Score for Crohn's disease (SES-CD) on an endoscopy confirmed by a central reader\n   * stool frequency (SF), abdominal pain (AP) score\n4. History of prior exposure to standard treatment (5-ASA, steroids, immunomodulators or antibiotics) or advanced therapies (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies\n5. On stable doses of standard treatments prior to screening (oral 5-ASA compounds, oral corticosteroids, thiopurines (eg. AZA, 6-MP), or MTX)\n6. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Participants with active UC, indeterminate colitis or short bowel syndrome\n2. Participants with CD isolated to the stomach, duodenum, jejunum, or peri anal region, without colonic or ileal involvement\n3. Participants with following ongoing known complications of CD: fistula, abscess, symptomatic stricture\u002Fstenosis, fulminant colitis, toxic megacolon, recent bowel resection within 3 months of screening or history of \\> 3 bowel resections\n4. Participants with stool sample positive for infectious pathogens\n5. Participants with active tuberculosis (TB) or a history of incompletely treated active or latent TB per local guidelines\n6. Participants with Positive Hepatitis B surface antigen (HBsAg) or positive Hepatitis B core antibody (HBcAb); and\u002For positive Hepatitis C antibody (HCV) at the Screening Visit\n7. Participants with any other active, chronic or recurrent infection, including recurrent or disseminated herpes zoster or disseminated herpes simplex\n8. Participants with a known history of Human Immunodeficiency Virus (HIV) infection or positive HIV-1 or HIV-2 serology at screening\n9. Participants presenting with active malignancies, lymphoproliferative disease, or recurrence of either, within the 5 years before screening\n10. History of colonic mucosal dysplasia or presence of colonic mucosal dysplasia or adenomatous colonic polyps not removed during colonoscopy at screening visit\n11. Infection(s) requiring treatment with IV anti infectives within 30 days or oral\u002Fintramuscular anti-infectives within 14 days prior to the screening visit\n12. Participants requiring or receiving any parental nutrition and\u002For exclusive enteral nutrition\n13. Participants who received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to screening\n14. Participants who received fecal microbial transplantation within 30 days prior to screening\n15. Participants who have ever been exposed to natalizumab (Tysabri®) or oral carotegrast methyl (Carogra®)\n16. Participants who received IV corticosteroids within 14 days prior to screening or during screening period\n17. Participants who received therapeutic enema or suppository, other than required for colonoscopy within 14 days prior to screening or during screening\n18. Screening laboratory and other analyses show abnormal results\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","18 Years","75 Years",{"count":58,"type":21},260,"INTERVENTIONAL",[61],"PHASE2","This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in participants with moderate to severe CD.\n\nThis study will have an anticipated duration of up to 59 weeks which will include a screening period of 4 weeks (+7 calendar days if needed), followed by the Main Study (MS) treatment period, lasting 52 weeks, and a 2-week follow-up period after end of treatment for participants not enrolling in the Long Term Safety (LTS) study. The MS period includes a Double-Blind (DB) treatment period with 12 weeks of induction followed by 40 weeks of maintenance.\n\nAdditionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. The combined duration of the DB maintenance and OL periods cannot exceed 40 weeks, depending on when participants switch.",[64],"Crohn's Disease","2026-06-11",{"date":67,"type":38},"2026-06-12",{"date":69,"type":38},"2024-12-10",{"date":71,"type":21},"2029-05-23",{"name":73,"class":74},"Sanofi","INDUSTRY",139,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":59,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":46},"100594020","tolerance-and-efficacy-open-label-study-with-rv4421b-in-various-populations-with-atopic-dermatitis-for-12-weeks-100594020","NCT07014007","Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks","Open-label Study to Assess the Tolerance and Efficacy of the Product RV4421B-EV0407, Applied in Paediatric and Adult Populations With Mild to Moderate Atopic Dermatitis for 12 Weeks","Inclusion criteria:\n\n* Male or female, with any phototype according to Fitzpatrick classification aged:\n* Group 1 (infants group): from 3 months to 23 months old included\n* Group 2 (children group): from 24 months to 12 years old included\n* Group 3 (teenagers \\& adults group): from 13 years old\n* Subject with a diagnosis of atopic dermatitis according to the U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis (Williams HC, Burney PG, et al.).\n* Subject with studied areas (lesions and prevailing xerotic areas) limited up to 30% of the body surface area\n* Subject with mild to moderate Atopic Dermatitis\n\nCriteria related to treatments and\u002For products:\n\n• Topical corticosteroids treatments (following international treatment guidelines for each age sub-group and including investigator agreement) applied on AD lesions areas since 1 to 5 days before the inclusion and ongoing at the time of inclusion. \\*\n\n\\*The investigator will be authorized to adjust the treatment during the study.\n\nExclusion criteria:\n\nCriteria related to the skin condition or the disease:\n\n* Infant with Atopic Dermatitis lesions or prevailing xerotic areas located on the diaper (groups 1 \\& 2)\n* Subject with history of allergy or intolerance to any of the study product(s) ingredients or material used for the research\n* Subject having any other dermatologic condition than Atopic Dermatitis, or characteristics (like tattoo…) on the studied areas liable to interfere with the study assessments\n* Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements\n* Knowledge of Acquired Immunodeficiency Syndrome or Infectious (acute or chronic)\n\nCriteria related to treatments and\u002For products:\n\n* Systemic biological immunosuppressive treatment established or modified within 12 weeks before the inclusion or planned to be started during the study\n* Phototherapy performed within 4 weeks before the inclusion visit or planned to be started during the study\n* Systemic non-biological immunosuppressive treatment established or modified within 4 weeks before the inclusion or ongoing or planned to be started during the study\n* Systemic corticosteroids treatment established or modified within 4 weeks before the inclusion or ongoing or planned to be started during the study\n* Systemic antibiotics for dermatological purposes treatment established or modified within 2 weeks before the inclusion or ongoing or planned to be started during the study\n* Systemic antihistaminic treatment established or modified within 2 weeks before the inclusion\n* Topical treatments (immunomodulators (TIMs), non-steroidal anti-inflammatory, antihistaminic, antibiotics for dermatological purposes or antiseptics) applied on studied areas within 1 week before the inclusion or ongoing or planned to be started during the study\n* Any other topical treatment or product applied on studied areas incompatible with the study or liable to interfere with the study assessments according to the investigator, in the weeks prior to the inclusion visit, ongoing or planned to be started during the study\n* Skin care product (including moisturizer) applied on the whole body between the evening before the visit and the inclusion.\n* Water and\u002For any cleansing product, applied on the whole body within 4 hours before the inclusion visit. If there is no studied area on the face, the subject is allowed to do a light face wash without time restriction (especially in the morning of the visit).\n* Subject who plans to modify his\u002Fher usual moisturizer (allowed outside studied areas) and\u002For care habits during the study\n\nTreatment of the mother if the subject of group 1 and 2 is breastfed:\n\n* Systemic biological immunosuppressive treatment established or modified within 12 weeks before the inclusion or planned to be started during the study\n* Systemic non-biological immunosuppressive treatment established or modified within 4 weeks before the inclusion or planned to be started during the study\n* Systemic corticosteroids established or modified within 2 weeks before the inclusion or planned to be started during the study\n* Systemic antihistaminic established or modified within 2 weeks before the inclusion\n* Systemic antibiotics for dermatological purposes established or modified within 1 week before the inclusion or planned to be started during the study","3 Months",{"count":85,"type":21},105,[87],"NA","Pierre Fabre Laboratories have developed a cream with medical device status, RV4421B-EV0407 indicated for the treatment of eczemas, including atopic eczema, contact eczema and chronic hand eczema.\n\nThis product is already marketed in several countries. The objective of this clinical study is to evaluate the safety and efficacy of the study product when used alone or in association with topical corticosteroid therapy, in an ethnically diverse adult and pediatric population (including dark skin) and over a long period of time with a 12-week follow-up.\n\n5 visits are planned:\n\n* Visit 1: Inclusion visit (Day 1)\n* Visit 2: Intermediate visit (Phone visit - Between Day 8 and Day 15)\n* Visit 3: Intermediate visit (Day 29 ± 3 days)\n* Visit 4: Intermediate visit (Day 57 ± 3 days)\n* Visit 5: End of study visit (Day 85 ± 3 days)",[90],"Atopic Dermatitis",[90,92,93,94,95,96,97,98,99,100],"Eczema","Flare","Inflammatory skin disease","Altered skin barrier","Dryness","Itching","Redness","Stinging","Burning sensation","2026-05-04",{"date":103,"type":38},"2026-05-05",{"date":105,"type":38},"2025-09-30",{"date":107,"type":21},"2026-11",{"name":109,"class":74},"Pierre Fabre Dermo Cosmetique",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":59,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":46},"100623009","comparative-study-for-the-evaluation-of-a-new-medical-device-shampoo-on-the-treatment-of-head-lice-infestation-100623009","NCT07391059","Comparative Study for the Evaluation of a New Medical Device Shampoo on the Treatment of Head Lice Infestation","Randomized Medical Device Class IIa Clinical Investigation to Assess the Safety and Efficacy of a New Shampoo for Head Lice Treatment","Inclusion Criteria:\n\n* Healthy participant,\n* Female or male participants,\n* Aged 2 years and above (for participants in arms 1 and 2),\n* Aged 3 years and above (for participants in arms 3) ,\n* Participants with a slight to moderate lice infestation (According to EU norms: 0, 1, 2)\n* Participants with various hair types (from 1 to 3C in the hair scale below) and hair length (from short to mid length hair not exceeding shoulder).\n* Written informed consent for participants ≥18 years or legal guardian for participants \\\u003C18 years given freely and expressly before start of the clinical investigation.\n* Participant\u002FParticipant's legal guardian is psychologically able to understand the clinical investigation related information and to give written informed consent.\n* Participant\u002Fparticipant's legal guardian agreeing to follow the study requirements during the whole clinical investigation period.\n* Females of childbearing potential and sexually active should use a contraceptive regimen recognized as effective at least 4 weeks before the beginning of the clinical investigation and during the entire clinical investigation.\n* Female participants of childbearing potential, presenting with negative pregnancy test at inclusion.\n\nExclusion Criteria:\n\n* Pregnant or nursing woman or planning a pregnancy during the clinical investigation;\n* Participant who had been deprived of their freedom by an administrative or legal decision or major participant who is under guardianship;\n* Participant in a social or sanitary establishment;\n* Participant being in an exclusion period from a previous clinical investigation or who is currently participating to another clinical investigation on hair\u002Fscalp or who participated to another clinical clinical investigation on hair\u002Fscalp within 3 months before first visit.\n* Participant suspected to be non-compliant according to the Investigator's judgment.\n\n  * Participant allergic to any of the ingredients and\u002For materials of the intended to be used products (investigation device and anti-lice comb, comparative device, post-treatment shampoo).\n\nParticipant with curly hair (from 4A to 4C in the hair type scale).\n\n* Participant with hair length exceeding shoulder.\n* Participants with more than 24 lice on the head.\n* Participant suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the clinical investigation results.\n* Participant with a cutaneous disease on the studied zone (scalp and hair).\n* Severe scratches or open wounds\u002Fskin damage on the scalp (lice bites allowed however).\n* Participant with a known or suspected allergy to one or more of the components of the investigational or comparator devices.\n* Participant who has diabetes.\n* Participant with known or suspected immune deficiency or autoimmune disease.\n\nParticipant undergoing a topical treatment on the test area or a systemic treatment with:\n\n* anti-inflammatory medication and\u002For anti-histamines during the previous 2 weeks and during the clinical investigation;\n* corticosteroids during the 2 previous weeks and during the clinical investigation;\n* retinoids and\u002For immunosuppressors during the 3 previous months and during the clinical investigation ;\n* any medication stabilized for less than one month.\n* Participant who received an anti-lice treatment in the previous month.",{"count":118,"type":21},180,[87],"Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice). The most common symptom of infestation is pruritus (itching) on the head which normally intensifies 3 to 4 weeks after the initial infestation.\n\nThe test item has been developed with the ambition to offer a complete head lice treatment, whilst also offering ultimate convenience in use - making treatment of head lice infestation easy, and effective in few minutes.\n\nThe objectives of this clinical study are to assess the efficacy and the safety of a new Medical Device shampoo for lice infestation treatment compared to a comparator device, already in market.",[122],"Headlice","NOT_YET_RECRUITING","2026-02-05",{"date":126,"type":38},"2026-02-10",{"date":128,"type":21},"2026-02",{"date":130,"type":21},"2026-05",{"name":132,"class":74},"Perrigo CSCI",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":141,"sex":142,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":59,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":46},"100611372","clinical-investigation-to-evaluate-the-efficacy-and-safety-of-epilady-prototype-device-followed-by-application-of-a-topical-formula-on-depigmentation-of-lentigo-spots-100611372","NCT07239726","CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS","CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS IN HEALTHY WOMEN PARTICIPANTS - STUDY UNDER DERMATOLOGICAL CONTROL","EPILADY","Inclusion Criteria:\n\n* Healthy female participants aged between 35 and 70 years old at the time of inclusion.\n* All Fitzpatrick skin phototypes (I to VI) are eligible; groups I-II and V-VI should include at least one participant per group.\n* Presence of at least two solar lentigo (dark spots) on each hand or forearm, with each spot measuring less than 100 mm x 100 mm as assessed by the investigator.\n* Participant has read, understood, and accepted the constraints of the clinical investigation.\n* Participant has provided written informed consent to participate in the clinical investigation.\n* Participant is able to understand the language used in the investigational site and comprehend the information provided.\n* Participants are cooperative and compliant, aware of the clinical investigation requirements and willing to adhere to the full duration of participation and follow-up visits, in line with the CIP requirements.\n* Women of childbearing potential must commit to using an effective contraceptive method throughout the clinical investigation period and for at least three months prior to the inclusion visit, with no changes during that time.\n\nExclusion Criteria:\n\n* • Participants with dry or sensitive skin, as assessed by the investigator.\n\n  * Participants who have used cosmetic products with exfoliating or astringent claims on the hands within 4 weeks prior to the baseline visit.\n  * Participants who have used any home-use or professional low-level laser therapy (LLLT) or have participated in clinical studies involving LLLT within the 6 months preceding the baseline visit\n  * History of light-induced seizures or chronic migraine disorders.\n  * History of photosensitivity or photoallergic reactions.\n  * Presence of underlying dermatological conditions on the hands\u002Fforearms that, in the opinion of the investigator, could interfere with the clinical investigation assessments.\n  * A family history of melanoma in first- or second-degree relatives (parents or grandparents).\n  * Presence of excessive moles, non-lentigo pigmented lesions, tattoos, scars, or irritated skin in the test area that could affect the validity of the investigation.\n  * History of surgical procedures involving the areas designated for treatment.\n  * Participants who have been exposed to or plan to be exposed to sunbathing or artificial UV sources (e.g., mountain sports, phototherapy, tanning salons) within 1 month before the clinical investigation start or during the clinical investigation period.\n  * Use of suntan or self-tanning products within the 2 weeks preceding the baseline visit.\n  * Change in cosmetic habits (e.g., moisturizers, skincare, shower gels) during the 2 weeks prior to baseline.\n  * Use of any medications, topical treatments, skincare products, or aesthetic procedures listed in the CIP without observing the required wash-out periods, or unwillingness\u002Finability to comply with those restrictions during the clinical investigation.\n  * Participant who cannot be contacted by telephone in case of emergency\n  * Participant in an exclusion period or participating in another biomedical research clinical investigation (self-reported)\n  * Intellectual\u002Fmental inability to follow clinical investigation instructions (if suspected) or incapacitation.\n  * Participants working for the contract research organization (CIDP) in charge of this clinical investigation.",true,"FEMALE","35 Years","70 Years",{"count":146,"type":21},44,[87],"To assess the efficacy of the Epilady investigational device, used with and without a topical depigmenting formula, in reducing the appearance of lentigo spots on the hands and forearms of healthy female participants over an 84-day period",[150],"Solar Lentigo",[152,153],"solar lentigo,","Laser treatment","2025-11-16",{"date":156,"type":38},"2025-11-20",{"date":158,"type":21},"2026-01-07",{"date":160,"type":21},"2026-05-08",{"name":162,"class":74},"Cosmetique Active International",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":142,"minAge":55,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":59,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":46},"100610992","clinical-study-of-a-vaginal-gel-for-the-treatment-and-prevention-of-vaginal-infections-100610992","NCT07234786","Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections","Prospective, Multicentric, Single Arm Clinical Investigation to Assess the Effectiveness and Safety of Multi-Gyn FemiTotal for Treatment and Prevention of Vulvovaginal Candidiasis Symptoms and Bacterial Vaginosis.","Inclusion Criteria\n\n1. Age ≥ 18 years old.\n2. Women suffering from VVC or BV at the time of inclusion:\n3. For VVC: Subject with at least itching score \\> 2 and crumbly white discharge.\n4. For BV: Subject with at least 3 out of 4 Amsel criteria positive, with at least presence of clue cells (\\>20%).\n\n   Amsel criteria used for the study:\n   * Thin, white, yellow, homogeneous discharge,\n   * Clue cells on wet mount microscopy \\>20%,\n   * a vaginal fluid pH ≥4.5 when placing the discharge on litmus paper,\n   * Release fishy odor after adding 10% potassium hydroxide (KOH) solution to wet mount - also known as \"whiff test\".\n5. Subject having given freely and expressly her informed consent.\n6. Subject using a contraceptive regimen recognized as effective (pill, implant, Intra Uterine Device (IUD), condoms) since at least 12 weeks before inclusion visit and during the whole study.\n7. Subject cooperative and aware of the device's modalities of use and the necessity and duration of the follow-up visits so that perfect adhesion to the protocol can be expected\n\nExclusion Criteria:\n\n1. Pregnant or nursing woman or planning a pregnancy during the study.\n2. Subject suspected to be non-compliant according to the investigator's judgment.\n3. Subject enrolled in another clinical trial during the study period on the vaginal area.\n4. Subject having a known allergy or hypersensitivity to one of the components of the investigational device.\n5. Subject suffering from a sexually transmitted gynaecological infection, genital tract infection or aerobic vaginitis (including clinical obvious gonorrhoea, chlamydia trachomatis or mycoplasma genitalium infection with cervicitis, urethritis, salpingitis).\n6. Subject with current genital malignancies.\n7. Subject who had a chemotherapy treatment in the 6 months before inclusion.\n8. Subject who had a radiotherapy treatment in the genito-urinary area in the 12 months before inclusion.\n9. Subject using treatment for vaginal conditions, vaginal infections, or other intravaginal treatment at the time of inclusion.\n10. Subject using antibiotics for any reason in the 14 days before inclusion.\n11. Subject using vaginal douches and who do not wish to refrain using them during the clinical investigation.\n12. Subject with a pessary.\n13. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk",{"count":171,"type":21},80,[87],"The goal of this clinical trial is to assess the safety and efficacy of Multi-Gyn Femitotal to treat and prevent women suffering from bacterial vaginosis and vulvo vaginal candidiasis. 40 subjects with itching symptoms of VVC and 49 subjects with BV as confirmed using Amsel criteria will be included and will use the device for 7 days (treatment phase). If the VVC symptoms and BV are considered as cured 21 days after the beginning of treatment, the subjects will be followed-up until Month 4 after treatment initiation to check the re-occurrence of VVC and BV (prevention phase).The primary objective is to evaluate the effectiveness of Multi-Gyn FemiTotal for the treatment of Bacterial Vaginosis (BV) and relief of VulvoVaginal Candidiasis (VVC) itching, 21 days after treatment initiation.",[175,176],"Bacterial Vaginosis","Vaginal Candidiasis","2025-11-14",{"date":179,"type":38},"2025-11-18",{"date":181,"type":38},"2025-10-20",{"date":183,"type":21},"2027-03-31",{"name":185,"class":74},"Karo Pharma AB",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":59,"phases":196,"briefSummary":197,"conditions":198,"keywords":202,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":46},"100598428","comparison-of-a-cosmetic-serum-and-4-hydroquinone-for-treating-melasma-over-84-days-100598428","NCT07071363","COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS","COMPARATIVE EVALUATION OF THE DERMATOLOGICAL TOLERANCE AND EFFICACY OF A COSMETIC SERUM VERSUS A 4% HYDROQUINONE-BASED PRODUCT IN SUBJECTS WITH MELASMA, AFTER 84 DAYS OF USE - STUDY CONDUCTED UNDER DERMATOLOGICAL SUPERVISION","Inclusion Criteria:\n\nMale or female subjects, primarily female, aged 18 to 65 years at the time of inclusion\n\nFitzpatrick skin phototype II to V\n\nDiagnosed with mild to moderate epidermal or mixed-type facial melasma, confirmed by Wood's lamp examination\n\nmMASI score between 3.5 and 13 at baseline\n\nSubject is in general good health as assessed by the investigator based on medical history and clinical examination\n\nWilling to avoid excessive sun exposure and use only the provided SPF50+ sunscreen during the study\n\nAble to understand the study procedures and provide written informed consent\n\nWilling and able to comply with study procedures and scheduled visits\n\nWomen of childbearing potential must agree to use a reliable method of contraception for at least 3 months prior to and during the entire study duration\n\nExclusion Criteria:\n\nPresence of post-inflammatory hyperpigmentation (PIH), lentigines, or other non-melasma facial pigmentation\n\nUse of topical or systemic depigmenting treatments, retinoids, corticosteroids, or hormonal treatments within 4 weeks prior to baseline\n\nKnown allergy or hypersensitivity to any component of the investigational or comparator products\n\nExcessive sun exposure or use of tanning beds within 2 weeks before baseline or planned during the study\n\nActive skin diseases (e.g., atopic dermatitis, psoriasis) or damaged skin in the test area\n\nPregnant or breastfeeding women, or those planning to become pregnant during the study\n\nParticipation in another clinical trial within 4 weeks prior to the study or planned participation in another trial during the study\n\nHistory of malignancy in the past 10 years (except treated basal cell carcinoma)\n\nUncontrolled systemic illness (e.g., diabetes, cardiovascular, hepatic, renal, or pulmonary disease)\n\nAny psychological or cognitive condition that would limit the subject's ability to understand the study procedures\n\nCurrent use of photosensitizing medications\n\nBMI \\> 40 or other conditions that may affect protocol compliance as judged by the investigator","65 Years",{"count":195,"type":21},40,[87],"The goal of this clinical trial is to compare the dermatological tolerance and skin-lightening efficacy of a cosmetic depigmenting serum to a 4% hydroquinone-based product in adult male and female subjects aged 18-65 years with mild to moderate epidermal or mixed-type melasma.\n\nThe main questions it aims to answer are:\n\nDoes the cosmetic serum reduce the severity of melasma (measured by mMASI) after 84 days of use?\n\nIs the cosmetic serum better tolerated than 4% hydroquinone under real-use conditions?\n\nResearchers will compare the serum group and the hydroquinone group to determine whether the cosmetic product achieves comparable pigmentation improvement with superior skin tolerability.\n\nParticipants will:\n\nGroup 1: Apply a morning routine (Depiwhite Serum + Depiwhite M SPF50+ cream) Apply an evening routine (Depiwhite Serum + Placebo Cream without Hydroquinone)\n\nGroup 2: Apply a morning routine (Serum Placebo + Depiwhite M SPF50+ cream) Apply an evening routine (Serum Placebo + Depigmenting Cream with hydroquinone 4%)\n\nVisit the clinical site at baseline (Day 0), Day 56, and Day 84 for assessments\n\nComplete standardized photographs, self-assessment questionnaires, and quality-of-life surveys (MELASQoL and ASLQI)\n\nUndergo clinical evaluations by a dermatologist, including mMASI scoring and tolerance assessment",[199,200,201],"Healthy","Melasma (Facial Melasma)","Epidermal Melasma",[203,204,205],"Melasma","Hyperpigmentation Skin","Pigmentation Disorders","2025-08-15",{"date":208,"type":38},"2025-08-20",{"date":210,"type":38},"2025-06-23",{"date":212,"type":21},"2025-12-22",{"name":214,"class":74},"Laboratoire Dermatologique ACM",""]